ArticleProceedings of the National Academy of Sciences of the United States of America2008
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 76 citations in OpenAlex.
- Trial
- Bacteriophage-based particles carrying the TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery in hepatocellular carcinoma.Nanoscale · 2024Article
- MMCL-CDR: enhancing cancer drug response prediction with multi-omics and morphology images contrastive representation learning.Bioinformatics (Oxford, England) · 2023Article
- Ewing sarcoma treatment: a gene therapy approach.Cancer gene therapy · 2023Review
- Transmorphic phage-guided systemic delivery of TNFα gene for the treatment of human pediatric medulloblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Review
- Bacteriophage-Mediated Cancer Gene Therapy.International journal of molecular sciences · 2022Review
- Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX).NPJ breast cancer · 2021Article
- Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Microbiota and Colorectal Cancer: From Gut to Bedside.Frontiers in pharmacology · 2021Review
- The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling.Frontiers in cell and developmental biology · 2021Review
- Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors.International journal of molecular sciences · 2020Article
- Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Review
- Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.EMBO molecular medicine · 2019Article
- Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine.Oncology letters · 2019Review
- Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.Biomaterials · 2018Article
- An AAVP-based solid-phase transducing matrix for transgene delivery: potential for translational applications.Cancer gene therapy · 2017Article
- Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.